Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Sclerosis-Relapsing-Remitting Clear all
Completed Phase 4 Interventional

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

NCT00206648
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaferon/Betaseron
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

NCT02038049
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Long Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 27, 2026, 5:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Early Phase 1 Interventional

Combination Therapy Using Cellcept and Rebif in RRMS

NCT00618527
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
mycophenolate mofetil (Cellcept), human interferon beta 1a (Rebif)
Drug
Lead sponsor
Aaron Boster
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Bazedoxifene Acetate
Drug
Lead sponsor
Riley Bove, MD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

NCT01695434
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

NCT00813969
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Autologous mesenchymal stem cell transplantation
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 27, 2026, 5:07 AM EDT
Withdrawn No phase listed Observational

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

NCT01539395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MSDx Complex-1 Biomarker Test
Other
Lead sponsor
MSDx, Inc.
Industry
Eligibility
45 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

NCT03983681
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
East Hanover, New Jersey • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Not listed Not applicable Interventional

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

NCT00210301
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Provigil (modafinil)
Drug
Lead sponsor
Institute for Clinical Research
Other
Eligibility
20 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis

NCT04972929
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Spinal Manipulation, Sham Spinal Manipulation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

NCT06220669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
LY3541860, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

NCT02217982
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Simethicone, Loperamide, Peanut Butter
Drug · Other
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

NCT06919900
View directory record Official record
Conditions
Multiple Sclerosis (Relapsing Remitting)
Interventions
Perturbation Training, Treadmill Walking
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 89 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

NCT04380220
View directory record Official record
Conditions
Multiple Sclerosis, Relapse
Interventions
Blood samples and processing
Diagnostic Test
Lead sponsor
Regina Elena Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 27, 2026, 5:07 AM EDT
Completed No phase listed Observational

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00206635
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
33 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS

NCT04032171
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 1 Interventional

Oral Guanabenz for Multiple Sclerosis

NCT02423083
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Interventions
Guanabenz
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 27, 2026, 5:07 AM EDT